Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated just now
PreprintAll rights reservedbioRxiv

Tamoxifen and Doxorubicin Synergistically Target Estrogen Receptor beta-Mutant p53-p73 Axis, a Therapeutically Actionable Vulnerability in Triple Negative Breast Cancer

  • G. M. Das1
  • C. C. Oturkar
  • J. H. Park
  • C. Adams
  • I. Ijaz
  • M. Oshi
  • M. Dolan
  • A. Caradori
  • Y. Zhang
  • J. Wang
  • B. Boleslav
  • D. Mager
11 more authors
  • A. Nair
  • T. Samanta
  • K. H. Jung
  • S. Y. Han
  • S. Yang
  • A. Tiwari
  • R. Mishra
  • J. Ebos
  • K. Attwood
  • K. Takabe
  • B. A. Kaipparettu
  1. 1Roswell Park Comprehensive Cancer Center
Read full textPDFDOICite

Related

  1. Emerging concepts on one-carbon metabolism as a unique and actionable vulnerability in cancer.
    Mathew Schneider, Zhanjun Hou, Larry H Matherly
    ASPET discoveryPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  2. Diagnostic Assessment of Tamoxifen-Associated Endometrial Pathology: A Narrative Review of Biomarkers, Risk Models, and Translational Gaps
    Diagnostics (Basel, Switzerland)Peer-reviewedCC BYFull textGeneral medicineEurope PMC
  3. Ophthalmic Encounters After Tamoxifen Initiation
    Siddharth Gandhi, Michael Balas, Patrick Wang +3
    JAMA OphthalmologyPeer-reviewedLicence not statedFull textObstetrics, gynaecology & paediatricsPMC
  4. The effectiveness of a therapeutically applied Dungeons and Dragons group intervention in a community mental health setting – Protocol for a randomised controlled trial.
    Terry Rae, Matthew Modini, Poppy Watson
    PsyArXivPreprintCC BY 4.0Full textPsychiatry & mental healthOSF
  5. The Osteosarcoma Tumor Microenvironment: Supportive of Tumor Progression, Hostile to Immunity, but Therapeutically Targetable.
    Lidia Tarone, Irene Fiore Merighi, Elisa Tirtei +4
    CancersPeer-reviewedCC BYFull textOncologyEurope PMCCrossref

Cite

BibTeXRIS
BibTeX
@misc{das2026tamoxifen,
  title = {{Tamoxifen and Doxorubicin Synergistically Target Estrogen Receptor beta-Mutant p53-p73 Axis, a Therapeutically Actionable Vulnerability in Triple Negative Breast Cancer}},
  author = {G. M. Das and C. C. Oturkar and J. H. Park and C. Adams and I. Ijaz and M. Oshi and M. Dolan and A. Caradori and Y. Zhang and J. Wang and B. Boleslav and D. Mager and A. Nair and T. Samanta and K. H. Jung and S. Y. Han and S. Yang and A. Tiwari and R. Mishra and J. Ebos and K. Attwood and K. Takabe and B. A. Kaipparettu},
  howpublished = {bioRxiv},
  year = {2026},
  month = oct,
  doi = {10.64898/2026.10.21.760572},
  url = {https://www.biorxiv.org/content/10.64898/2026.10.21.760572v1},
}
RIS
TY  - UNPB
TI  - Tamoxifen and Doxorubicin Synergistically Target Estrogen Receptor beta-Mutant p53-p73 Axis, a Therapeutically Actionable Vulnerability in Triple Negative Breast Cancer
AU  - G. M. Das
AU  - C. C. Oturkar
AU  - J. H. Park
AU  - C. Adams
AU  - I. Ijaz
AU  - M. Oshi
AU  - M. Dolan
AU  - A. Caradori
AU  - Y. Zhang
AU  - J. Wang
AU  - B. Boleslav
AU  - D. Mager
AU  - A. Nair
AU  - T. Samanta
AU  - K. H. Jung
AU  - S. Y. Han
AU  - S. Yang
AU  - A. Tiwari
AU  - R. Mishra
AU  - J. Ebos
AU  - K. Attwood
AU  - K. Takabe
AU  - B. A. Kaipparettu
PY  - 2026
DA  - 2026/10/21
PB  - bioRxiv
DO  - 10.64898/2026.10.21.760572
UR  - https://www.biorxiv.org/content/10.64898/2026.10.21.760572v1
ER  -